Data Sheet 1_Socioeconomic drivers of encephalitis burden in the post-COVID era: a 204-country analysis from global burden of disease study 2021.pdf by Yikang Wang (2188945)

“…Background<p>Encephalitis, an inflammatory central nervous system disease causing significant morbidity and mortality, disproportionately affects low- and middle-income countries (LMICs) due to healthcare disparities. …”

Data Sheet 4_Socioeconomic drivers of encephalitis burden in the post-COVID era: a 204-country analysis from global burden of disease study 2021.pdf by Yikang Wang (2188945)

“…Background<p>Encephalitis, an inflammatory central nervous system disease causing significant morbidity and mortality, disproportionately affects low- and middle-income countries (LMICs) due to healthcare disparities. …”

Data Sheet 6_Socioeconomic drivers of encephalitis burden in the post-COVID era: a 204-country analysis from global burden of disease study 2021.zip by Yikang Wang (2188945)

“…Background<p>Encephalitis, an inflammatory central nervous system disease causing significant morbidity and mortality, disproportionately affects low- and middle-income countries (LMICs) due to healthcare disparities. …”

Data Sheet 2_Socioeconomic drivers of encephalitis burden in the post-COVID era: a 204-country analysis from global burden of disease study 2021.pdf by Yikang Wang (2188945)

“…Background<p>Encephalitis, an inflammatory central nervous system disease causing significant morbidity and mortality, disproportionately affects low- and middle-income countries (LMICs) due to healthcare disparities. …”

Data Sheet 5_Socioeconomic drivers of encephalitis burden in the post-COVID era: a 204-country analysis from global burden of disease study 2021.pdf by Yikang Wang (2188945)

“…Background<p>Encephalitis, an inflammatory central nervous system disease causing significant morbidity and mortality, disproportionately affects low- and middle-income countries (LMICs) due to healthcare disparities. …”

Data Sheet 3_Socioeconomic drivers of encephalitis burden in the post-COVID era: a 204-country analysis from global burden of disease study 2021.pdf by Yikang Wang (2188945)

“…Background<p>Encephalitis, an inflammatory central nervous system disease causing significant morbidity and mortality, disproportionately affects low- and middle-income countries (LMICs) due to healthcare disparities. …”

Image 6_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.png by Jia-Xin Zhang (1833157)

“…However, there is still debate about the risk of new-onset inflammatory bowel disease (IBD) in psoriasis patients following interleukin inhibitor treatment. …”

Image 3_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.png by Jia-Xin Zhang (1833157)

“…However, there is still debate about the risk of new-onset inflammatory bowel disease (IBD) in psoriasis patients following interleukin inhibitor treatment. …”

Image 4_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.png by Jia-Xin Zhang (1833157)

“…However, there is still debate about the risk of new-onset inflammatory bowel disease (IBD) in psoriasis patients following interleukin inhibitor treatment. …”

Image 5_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.png by Jia-Xin Zhang (1833157)

“…However, there is still debate about the risk of new-onset inflammatory bowel disease (IBD) in psoriasis patients following interleukin inhibitor treatment. …”

Table 1_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.docx by Jia-Xin Zhang (1833157)

“…However, there is still debate about the risk of new-onset inflammatory bowel disease (IBD) in psoriasis patients following interleukin inhibitor treatment. …”

Image 1_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.png by Jia-Xin Zhang (1833157)

“…However, there is still debate about the risk of new-onset inflammatory bowel disease (IBD) in psoriasis patients following interleukin inhibitor treatment. …”

Table 2_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.docx by Jia-Xin Zhang (1833157)

“…However, there is still debate about the risk of new-onset inflammatory bowel disease (IBD) in psoriasis patients following interleukin inhibitor treatment. …”

Image 2_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.png by Jia-Xin Zhang (1833157)

“…However, there is still debate about the risk of new-onset inflammatory bowel disease (IBD) in psoriasis patients following interleukin inhibitor treatment. …”

Video 1_Dual diagnosis at the neuro-immune interface: a case report of neuronal intranuclear inclusion disease with acute anti-CASPR2 encephalitis.mp4 by Wan Zhu (166878)

“…<p>Neuronal intranuclear inclusion disease (NIID) is a rare autosomal-dominant, progressive neurodegenerative condition characterized by complex and variable clinical manifestations that can affect multiple neurological domains. …”

Table 5_The cellular and extracellular proteomic signature of human dopaminergic neurons carrying the LRRK2 G2019S mutation.docx by Felix Knab (4459465)

“…Genetic variants in the LRRK2 gene have been linked to both familial and sporadic forms of Parkinson’s disease. With LRRK2 inhibitors entering clinical trials, there is an unmet need for biomarkers that reflect LRRK2-specific pathology and target engagement.…”

Table 4_The cellular and extracellular proteomic signature of human dopaminergic neurons carrying the LRRK2 G2019S mutation.docx by Felix Knab (4459465)

“…Genetic variants in the LRRK2 gene have been linked to both familial and sporadic forms of Parkinson’s disease. With LRRK2 inhibitors entering clinical trials, there is an unmet need for biomarkers that reflect LRRK2-specific pathology and target engagement.…”

Table 7_The cellular and extracellular proteomic signature of human dopaminergic neurons carrying the LRRK2 G2019S mutation.docx by Felix Knab (4459465)

“…Genetic variants in the LRRK2 gene have been linked to both familial and sporadic forms of Parkinson’s disease. With LRRK2 inhibitors entering clinical trials, there is an unmet need for biomarkers that reflect LRRK2-specific pathology and target engagement.…”

Table 1_The cellular and extracellular proteomic signature of human dopaminergic neurons carrying the LRRK2 G2019S mutation.docx by Felix Knab (4459465)

“…Genetic variants in the LRRK2 gene have been linked to both familial and sporadic forms of Parkinson’s disease. With LRRK2 inhibitors entering clinical trials, there is an unmet need for biomarkers that reflect LRRK2-specific pathology and target engagement.…”

Table 6_The cellular and extracellular proteomic signature of human dopaminergic neurons carrying the LRRK2 G2019S mutation.docx by Felix Knab (4459465)

“…Genetic variants in the LRRK2 gene have been linked to both familial and sporadic forms of Parkinson’s disease. With LRRK2 inhibitors entering clinical trials, there is an unmet need for biomarkers that reflect LRRK2-specific pathology and target engagement.…”